Record title
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Record identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5264219
Record permalink
https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5264219
Share
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
About this item
Full title
Author / Creator
Publisher
England: British Medical Association
Journal title
Record Identifier
Language
English
Formats
Publication information
Publisher
Subjects
More information
Scope and Contents
Contents
Alternative Titles
Full title
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5264219
Permalink
https://collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5264219
Other Identifiers
ISSN
E-ISSN
DOI
